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Introduction
Allergic asthma is a chronic inflammatory respiratory
disease associated with eosinophilic infiltration,
increased mucus production, airway
hyperresponsiveness (AHR), and airway remodeling.
Lung airway epithelial cells express a myriad of pattern
recognition receptors such as Toll-like receptors (TLRs),
enabling them to sense and respond to a variety of
external triggers. The epithelial-derived cytokines IL-33,
TSLP, and IL-25 are widely recognized as alarmins
produced in response to house-dust mites (HDM).
These cytokines activate several leukocytes involved in
allergic inflammation, such as eosinophils. We have
shown that a combination of Pam2CSK4 (“Pam2”,
TLR2/6 ligand) and a class C oligodeoxynucleotide
ODN M362 (“ODN”, TLR9 ligand) when delivered
together by aerosol (“Pam2ODN”) synergistically
activate an innate immune response in the lung
mucosa. To further study the immunomodulatory effects
of Pam2ODN, we have developed allergic models to
show that Pam2ODN attenuates an allergic immune
response to HDM.

Methods
Mice were sensitized with 100 μg HDM extract at day 0,
followed by 6 daily challenges of 10 μg HDM from day 7
to 12. Mice were suspended from upper incisors on a
board 60 degrees from 0, under isoflurane anesthesia.
Mice were challenged with HDM mixed in PBS while
suspended from upper incisors at 60 degrees by placing
individual droplets onto nose, while under isoflurane
anesthesia. Bronchoalveolar lavage was done on mice
after challenges were completed. Differential cell
quantification with Wright-Giemsa stain was done to
evaluate numbers of leukocytes in bronchoalveolar
lavage fluid. Mucous metaplasia of lung epithelial cells
was assessed by staining lung tissue with fluorescent
PAS stain. Mice were given Pam2ODN at intervals
before and after sensitization to HDM. To evaluate
synergy, Pam2 and ODN were aerosolized individually
or in combination with the previous sensitization and
challenge paradigm.

Figure 3. Pam2 and ODN cooperate synergistically to block
sensitization to HDM. Pam2, ODN, or Pam2ODN was
administered 7 days before sensitization to HDM. Quantification
of leukocytes in lung lavage for (A) eosinophils, (B) macrophages,
(C), lymphocytes, and (D) neutrophils (N = 3-5 mice). Bars show
mean +/- SEM. P* < 0.005 for synergy between Pam2 and ODN
by linear regression.

Results
When mice were treated with a single Pam2ODN
treatment 7 days before HDM sensitization, we
observed strong reductions in leukocytes collected in
lung lavage fluid, compared to HDM/HDM mice (Figure
1). Differential cell quantification with Wright-Giemsa
stain revealed an overall decrease in leukocyte
Figure 1. Exposure to Pam2-ODN prevents allergic inflammation to HDM. (A) HDM experimental paradigm with a
recruitment (Figures 1C-1F). Quantitative image
sensitization of 100 µg HDM and challenges of 10 µg HDM. (B) Leukocytes obtained by lung lavage were pelleted onto glass
analysis of intracellular mucin content revealed that
slides by centrifugation and stained with Wright-Giemsa. Scale bar = 20 μm. (C-F) Quantification of leukocytes in lung lavage
intracellular mucin accumulates moderately in
for (C) eosinophils, (D) lymphocytes, (E) macrophages, and (F) neutrophils (N = 3-5 mice). (G-H) Airways stained with H&E to
demonstrate submucosal inflammation. Scale bar = 20 μm (I) Airway epithelium stained with PAFS to demonstrate intracellular PBS/HDM mice, but HDM sensitization was required for
the full phenotype (Fig. 1J). A single Pam2ODN
mucin in red. Scale bar = 20 μm. (J) Quantification of intracellular mucin content by image analysis of airway (N = 3-5 mice).
treatment 7 days before HDM sensitization reduced
Bars show mean +/- SEM. P* < 0.05 by one-way ANOVA with Dunnett’s test for multiple comparisons against [HDM/HDM]
intracellular epithelial mucin content >35%, which was
control.
not significantly different from PBS/HDM mice.
Figure 2. Pam2-ODN
Pam2ODN treatments similarly showed efficacy when
prevents sensitization to
administered 30- and 15-days before sensitization, with
HDM. (A-B) Quantification of
a trend toward less efficacy when the treatmentleukocytes in lung lavage
sensitization interval was further increased. When
when a single Pam2-ODN
Pam2ODN treatment was administered any day after
treatment was administered
HDM sensitization, the treatment effect was completely
before or after sensitization
absent (Figure 2A). Neither Pam2 nor ODN exhibited
to HDM (N = 3-5 mice). (B)
any significant efficacy when administered alone, but
Quantification of lung
the combination Pam2ODN treatment completely
leukocytes when 6
consecutive daily Pam2blocked allergic inflammation (Fig 3A-D).
ODN treatments were
administered after
sensitization to HDM during
the first week (days +1:6) or
concurrently with challenge
(days +7:12). Pictograms
show blue bar at the
approximate range of Pam2ODN exposure in
relationship to sensitization
and challenge. Bars show
mean +/- SEM. P* < 0.05 by
one-way ANOVA with
Dunnett’s test for multiple
comparisons against
[HDM/HDM] control.

Conclusions
With the results from this study, we have generated
evidence that Pam2ODN induces a powerful immune
response that interferes with allergic inflammation in
mice. Pam2ODN is only able to attenuate allergic
inflammation when administered before HDM
sensitization, which suggests that the mechanism of
action involves blocking sensitization to HDM. It is
possible that Pam2ODN might induce tolerance to
aeroallergens and could be useful as a therapeutic for
allergic disease.

